Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Page 1257, November 2009

Reply

  • Sarah Caspersen, MD

      Affiliations

    • Department of Medical Gastroenterology, University of Copenhagen, Herlev, Denmark
    • ,
  • Christian Mortensen, MD

      Affiliations

    • Department of Medical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark
    • ,
  • Lene Riis, MD

      Affiliations

    • Department of Medical Gastroenterology, University of Copenhagen, Herlev, Denmark
    • ,
  • Tine Jess, MD

      Affiliations

    • Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark
    • ,
  • Flemming Bendtsen

      Affiliations

    • Department of Medical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark

published online 23 September 2009.

The following reply refers to a letter to the editor (de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603–604) published in the May 2009 issue of Clinical Gastroenterology and Hepatology.

 

 Conflicts of interest The authors disclose the following: Dr Caspersen has received travel grants and payment for oral presentations from Schering-Plough, Denmark. Dr Bendtsen is a member of an advisory board for Schering-Plough, Denmark. The remaining authors disclose no conflicts.

PII: S1542-3565(09)00909-4

doi:10.1016/j.cgh.2009.09.016

Refers to article:

  • Safety of Infliximab in Inflammatory Bowel Disease Needs to Be Debated , 29 December 2008

    Hilbert S. de Vries, Martijn G.H. Van Oijen, Dirk J. de Jong
    Clinical Gastroenterology and Hepatology May 2009 (Vol. 7, Issue 5, Pages 603-604)

Clinical Gastroenterology and Hepatology
Volume 7, Issue 11 , Page 1257, November 2009